67 related articles for article (PubMed ID: 11527011)
21. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.
Larrauri A; Cano R; García M; Mateo Sd
Vaccine; 2005 Jul; 23(32):4097-100. PubMed ID: 15908059
[TBL] [Abstract][Full Text] [Related]
22. The strategy to control New Zealand's epidemic of group B meningococcal disease.
O'Hallahan J; Lennon D; Oster P
Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S293-8. PubMed ID: 15597072
[TBL] [Abstract][Full Text] [Related]
23. [Acceptance of the new conjugate vaccines. Meningococcal and pneumococcal vaccines, in the cohort born in 1999, in the North Region of Portugal].
De Queirós L; Castro L; Ferreira MC; Gonçalves G
Acta Med Port; 2004; 17(1):49-53. PubMed ID: 15636727
[TBL] [Abstract][Full Text] [Related]
24. Meningococcal vaccines.
Danzig L
Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S285-92. PubMed ID: 15597071
[TBL] [Abstract][Full Text] [Related]
25. A clinical trial examining the effect of increased total CRM(197) carrier protein dose on the antibody response to Haemophilus influenzae type b CRM(197) conjugate vaccine.
Usonis V; Bakasenas V; Lockhart S; Baker S; Gruber W; Laudat F
Vaccine; 2008 Aug; 26(35):4602-7. PubMed ID: 18577410
[TBL] [Abstract][Full Text] [Related]
26. Etanercept Immunex.
Yung RL
Curr Opin Investig Drugs; 2001 Feb; 2(2):216-21. PubMed ID: 11816834
[TBL] [Abstract][Full Text] [Related]
27. Serologic correlates of protection for evaluating the response to meningococcal vaccines.
Balmer P; Borrow R
Expert Rev Vaccines; 2004 Feb; 3(1):77-87. PubMed ID: 14761245
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
[TBL] [Abstract][Full Text] [Related]
29. Recent trends in meningococcal epidemiology and current vaccine recommendations.
Baltimore RS
Curr Opin Pediatr; 2006 Feb; 18(1):58-63. PubMed ID: 16470164
[TBL] [Abstract][Full Text] [Related]
30. Gastrin 17 vaccine--Aphton: Anti-gastrin 17 immunogen, G17DT.
BioDrugs; 2003; 17(3):223-5. PubMed ID: 12749761
[TBL] [Abstract][Full Text] [Related]
31. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C.
Costantino P; Viti S; Podda A; Velmonte MA; Nencioni L; Rappuoli R
Vaccine; 1992; 10(10):691-8. PubMed ID: 1523880
[TBL] [Abstract][Full Text] [Related]
32. Cytomegalovirus glycoprotein vaccine (Chiron).
Drugs R D; 1999 Nov; 2(5):308-9. PubMed ID: 10728467
[No Abstract] [Full Text] [Related]
33. [Strategy in meningococcus-prophylaxis].
Midtvedt T
Tidsskr Nor Laegeforen; 1970 Dec; 90(24):2284-5. PubMed ID: 5489623
[No Abstract] [Full Text] [Related]
34. Chiron buys PathoGenesis.
Nat Biotechnol; 2000 Oct; 18(10):1023. PubMed ID: 11016999
[No Abstract] [Full Text] [Related]
35. Chiron and His Pupil Asclepius.
Gilruth JD
Ann Med Hist; 1939 Mar; 1(2):158-176. PubMed ID: 33943414
[No Abstract] [Full Text] [Related]
36. Correction to: Chiron: translating nanopore raw signal directly into nucleotide sequence using deep learning.
Teng H; Cao MD; Hall MB; Duarte T; Wang S; Coin LJM
Gigascience; 2019 May; 8(5):. PubMed ID: 31077312
[No Abstract] [Full Text] [Related]
37. Meningitis C vaccine (North American vaccine).
Lattanzi M; Del Giudice G
Curr Opin Investig Drugs; 2002 Jan; 3(1):51-3. PubMed ID: 12054072
[TBL] [Abstract][Full Text] [Related]
38. Intranasal immunization with dry powder vaccines.
Bahamondez-Canas TF; Cui Z
Eur J Pharm Biopharm; 2018 Jan; 122():167-175. PubMed ID: 29122735
[TBL] [Abstract][Full Text] [Related]
39. Menjugate (Chiron).
Jones DH
Curr Opin Investig Drugs; 2001 Jan; 2(1):47-9. PubMed ID: 11527011
[TBL] [Abstract][Full Text] [Related]
40. Serogroup C meningococcal conjugate vaccines: new preparations. Effective from age two months.
Prescrire Int; 2003 Apr; 12(64):43-6. PubMed ID: 12675020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
